Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013;17(1):6-13.
doi: 10.5114/wo.2013.33766. Epub 2013 Mar 15.

The antineoplastic effect of low-molecular-weight heparins - a literature review

Justyna Bochenek  1 , Mirosława Püsküllüoğlu, Krzysztof Krzemieniecki
Affiliations

The antineoplastic effect of low-molecular-weight heparins - a literature review

Justyna Bochenek et al. Contemp Oncol (Pozn). 2013.

Abstract

There is some evidence for the antitumor effect of heparins, especially the low-molecular-weight ones. The authors discuss the potential mechanism of this antineoplastic effect and present results from several in vitro and in vivo experiments. The clinical trials concerning the impact of low-molecular-weight heparins on the tumor and on the patients' survival are described. The objective was to find out if heparins could be administered as an antitumor drug, independently of their anticoagulatory properties. The antitumor role of tissue factor, heparinase, chemokines, stromal proteins, cellular interactions as well as angiogenesis and immunology seems certain. The results of the available studies seem promising but large clinical trials are necessary in order to confirm the antineoplastic effect of the low-molecular-weight heparins and to approve them for standard anticancer treatment. It could be a breakthrough in modern oncology.

Keywords: cancer; cellular interactions; chemokines; heparins; tissue factor; venous thromboembolism.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Potential mechanisms of the anticancer action of the low-molecular-weight heparins
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest. 1980;65:64–73. - PMC - PubMed
    1. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119(1 Suppl):64S–94S. - PubMed
    1. Andersson LO, Barrowcliffe TW, Holmer E, Johnson EA, Söderström G. Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma. Thromb Res. 1979;15:531–41. - PubMed
    1. Kelton JG, Hirsh J. Bleeding associated with antithrombotic therapy. Semin Hematol. 1980;17:259–1. - PubMed
    1. Blajchman MA, Young E, Ofosu FA. Effects of unfractionated heparin, dermatan sulfate and low molecular weight heparin on vessel wall permeability in rabbits. Ann NY Acad Sci. 1989;556:245–54. - PubMed

LinkOut - more resources